- SHIFT is the basis for a prognostic model for heart failure patients
- Ivabradine safely and significantly improves heart rate variability parameters
- The efficacy and safety of ivabradine is independent of baseline blood pressure
- Ivabradine’s clinical benefits in CHF are maintained with or without renal dysfunction
- Ivabradine improves clinical outcomes independently of heart failure severity
- Ivabradine is similarly effective in chronic heart failure patients with or without COPD
- Age does not limit the appropriate use of ivabradine in patients with chronic heart failure and systolic dysfunction